Does Phosphatidylcholine Cognition Meta-Analysis work?

The current Migaku evidence database contains 2 reusable source documents for Phosphatidylcholine Cognition Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove. - We searched PubMed and Google Scholar from database inception to Dec 1, 2025, for studies in any language using the search terms (“metabolomics” OR “metabolomic profile” OR “plasma metabolites”) AND (“hip fracture” OR “osteoporosis fracture” OR “bone fracture risk”). [Wu Zhiyuan (2026); evidence level 3] - However, we identified no large-scale prospective studies that systematically examined the association between a wide range of plasma metabolites and the risk of hip fracture. [Wu Zhiyuan (2026); evidence level 3] - In particular, the role of phospholipid metabolism in relation to hip fracture risk had not been well established. [Wu Zhiyuan (2026); evidence level 3] - Previous metabolomics studies have reported associations of certain metabolites with bone mineral density and osteoporosis in general. [Wu Zhiyuan (2026); evidence level 3] - However, its metabolite trimethylamine N-oxide is considered a potential cardiovascular risk factor. [Wang W (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.